Recognizing the duty of the Federal Government to lead the world in biomedical research.

Diana DeGette

Democrat · CO · Representative

Source: Congress.gov · FEC

2 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.

Referred to the House Committee on Energy and Commerce.

2025-07-23

Source: Congress.gov

The federal government would commit to maintaining and expanding its leadership role in biomedical research, which includes funding through agencies like the National Institutes of Health to develop new treatments and cures for diseases. This affects researchers, pharmaceutical companies, patients seeking new medical treatments, and taxpayers who fund these research initiatives. The measure emphasizes that the U.S. should compete globally in scientific discovery and medical innovation.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

• HR3491DeOndra Dixon INCLUDE Project Act of 2025
  Reported by Committee · 2026-07-02
• HR9392Medicare Advantage Cost Transparency Act
  Referred to Committee · 2026-06-25
• HRES1285Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
  Referred to Committee · 2026-05-14
• HR8432To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes.
  Referred to Committee · 2026-04-22